Abbott Laboratories Reaffirms FY23 Adj. EPS Outlook - Update
(RTTNews) - While reporting financial results for the second quarter on Thursday, Abbott Laboratories (ABT) reaffirmed its adjusted earnings guidance for the full-year 2023.
For fiscal 2023, the company now projects earnings in a range of $3.02 to $3.22 per share and adjusted earnings in a range of $4.30 to $4.50 per share.
Previously, the company expected earnings in the range of $3.05 to $3.25 per share and adjusted earnings in the range of $4.30 to $4.50 per share.
On average, 24 analysts polled by Thomson Reuters expect the company to report earnings of $4.40 per share for the year. Analysts' estimates typically exclude special items.
For more earnings news, earnings calendar, and earnings for stocks, visit rttnews.com
read more
Abbott Laboratories Boosts FY24 Earnings Outlook - Update
While reporting financial results for the second quarter on Thursday, Abbott Laboratories (ABT) provided earnings and adjusted earnings guidance for the third quarter and raised its outlook for the full-year 2024.
RTTNews
|
103 gün önce
Abbott Says FDA Approves First-of-Its-Kind TriClip Transcatheter Edge-to-edge Repair System
Abbott Laboratories (ABT) announced Tuesday that the U.S. Food and Drug Administration (FDA) has approved the company's first-of-its-kind TriClip transcatheter edge-to-edge repair (TEER) system that's specifically designed for the treatment of tricuspid regurgitation (TR), or a leaky tricuspid valve.
RTTNews
|
210 gün önce
Abbott Laboratories Guides FY24 Adj. EPS In Line With Estimates - Update
While reporting financial results for the fourth quarter on Wednesday, Abbott Laboratories (ABT) initiated earnings and adjusted earnings guidance for the full-year 2024.
RTTNews
|
279 gün önce
Abbott Inks Deal With MAbxience To Commercialize Biosimilar Molecules In Emerging Markets
Abbott Laboratories (ABT) announced Wednesday an agreement with Spain-based global biotech firm mAbxience Holdings S.L. to commercialize several biosimilars focusing on oncology, women's health and respiratory diseases in emerging markets.
RTTNews
|
405 gün önce
Abbott Laboratories Says FDA Approves Assert-IQ Insertable Cardiac Monitor
Abbott Laboratories (ABT) announced Thursday that its Assert-IQ insertable cardiac monitor (ICM) has received U.S. Food and Drug Administration (FDA) clearance, giving physicians a new option for diagnostic evaluation and long-term monitoring of people experiencing irregular heartbeats.
RTTNews
|
530 gün önce
Abbott Says FDA Approves Spinal Cord Stimulation Devices To Treat Chronic Back Pain
Abbott Laboratories (ABT) announced Tuesday that the U.S. Food and Drug Administration (FDA) has approved its spinal cord stimulation (SCS) devices for the treatment of chronic back pain in people who have not had or are not eligible to receive back surgery, known as non-surgical back pain.
RTTNews
|
532 gün önce
Abbott Announces Two New FDA Clearances For Life Support System
Abbott Laboratories (ABT) announced Tuesday two new clearances from the U.S. Food and Drug Administration (FDA) for the company's industry-leading life support system.
RTTNews
|
553 gün önce
Abbott Says FDA Oks Proclaim XR Spinal Cord Stimulation System To Treat DPN
Abbott Laboratories, Inc. (ABT) announced Thursday that the U.S. Food and Drug Administration (FDA) has approved its Proclaim XR spinal cord stimulation (SCS) system to treat painful diabetic peripheral neuropathy (DPN), a debilitating complication of diabetes.
RTTNews
|
642 gün önce
